Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of “Moderate Buy” from Analysts

Natera, Inc. (NASDAQ:NTRA) has been given an average recommendation of “Moderate Buy” by the eighteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $249.20.

A number of analysts have weighed in on the company. Evercore increased their price target on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Piper Sandler increased their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Finally, Morgan Stanley raised their price objective on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st.

Insider Activity at Natera

In other Natera news, CFO Michael Burkes Brophy sold 6,939 shares of Natera stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total value of $1,580,912.37. Following the completion of the sale, the chief financial officer directly owned 52,120 shares of the company’s stock, valued at approximately $11,874,499.60. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 1,639 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total transaction of $378,232.03. Following the transaction, the insider directly owned 137,847 shares in the company, valued at $31,810,952.19. This trade represents a 1.18% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 368,119 shares of company stock valued at $85,956,782. Company insiders own 5.63% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Palladiem LLC bought a new position in Natera in the 4th quarter valued at about $31,000. Bank of Jackson Hole Trust raised its stake in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Natera in the fourth quarter valued at approximately $39,000. Flagship Harbor Advisors LLC bought a new position in shares of Natera in the fourth quarter valued at approximately $41,000. Finally, Greenline Wealth Management LLC purchased a new position in shares of Natera during the fourth quarter valued at approximately $41,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Q4 earnings sharply beat expectations — Natera reported EPS of $0.35 versus consensus losses, and revenue of $665.5M, up 39.8% year‑over‑year, driven by product growth. This combination of an earnings surprise and strong top‑line growth is the main positive catalyst. Natera (NTRA) Tops Q4 Earnings and Revenue Estimates
• Positive Sentiment: Gross margins improved materially — the company reported a Q4 gross margin of ~66.9%, signaling better unit economics as volumes scale, which supports higher operating leverage going forward. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: FY‑2026 revenue guidance was provided in a range of ~$2.6B–$2.7B, roughly in line with Street expectations, giving investors more visibility on growth but not a material upside to consensus. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Management hosted an earnings call and published a slide deck and transcript — useful for details on adoption trends, margin drivers, and FY‑2026 assumptions; transcripts and call notes are available for deeper review. Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable on a net basis — despite the beat, Natera reported a negative net margin and negative return on equity, and its valuation metrics still reflect losses, which leaves upside dependent on sustaining margin expansion and converting revenues to net profits. Natera Q4 Earnings Snapshot / MarketBeat

Natera Stock Performance

Natera stock opened at $216.10 on Friday. The firm has a market cap of $29.89 billion, a price-to-earnings ratio of -94.37 and a beta of 1.64. Natera has a 52-week low of $125.38 and a 52-week high of $256.36. The firm has a 50 day moving average price of $227.00 and a two-hundred day moving average price of $203.19.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same period in the prior year, the company posted ($0.41) earnings per share. As a group, equities research analysts predict that Natera will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.